<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Differences in the clinical course of secondary <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> according to the type of the preceding disorders are not defined </plain></SENT>
<SENT sid="1" pm="."><plain>We compared the outcomes of therapy-related <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>, <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> following <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and <z:hpo ids='HP_0011009'>acute</z:hpo> myeloiod <z:hpo ids='HP_0001909'>leukemia</z:hpo> following myeloproliferative <z:hpo ids='HP_0002664'>neoplasm</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We also intended to find prognostic factors in secondary <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> overall </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Retrospective medical record review at Seoul National University Hospital was performed </plain></SENT>
<SENT sid="4" pm="."><plain>We assessed response to induction chemotherapy and overall survival </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Ninety-five secondary <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> patients (median age of 56.4 years) were analyzed </plain></SENT>
<SENT sid="6" pm="."><plain>Twenty-six, 57 and 12 patients had therapy-related <z:hpo ids='HP_0001909'>leukemia</z:hpo>, <z:hpo ids='HP_0001909'>leukemia</z:hpo> following <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and myeloproliferative <z:hpo ids='HP_0002664'>neoplasm</z:hpo>, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>For patients receiving induction chemotherapy, complete remission rate was 47.5% and complete remission rate was different according to the type of the preceding disorders (P = 0.004) </plain></SENT>
<SENT sid="8" pm="."><plain>Compared to therapy-related <z:hpo ids='HP_0001909'>leukemia</z:hpo> (P = 0.027) and <z:hpo ids='HP_0001909'>leukemia</z:hpo> following <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (P = 0.050), <z:hpo ids='HP_0001909'>leukemia</z:hpo> following myeloproliferative <z:hpo ids='HP_0002664'>neoplasm</z:hpo> had shorter overall survival </plain></SENT>
<SENT sid="9" pm="."><plain>In secondary <z:hpo ids='HP_0001909'>leukemia</z:hpo>, presence of <z:mp ids='MP_0004027'>trisomy</z:mp> 8 had a prognostic impact (P = 0.003) along with cytogenetic risk group (P = 0.016) </plain></SENT>
<SENT sid="10" pm="."><plain>In multivariate analysis, the type of the preceding disorders (P = 0.026), 5q deletion (P = 0.015) and <z:mp ids='MP_0004027'>trisomy</z:mp> 8 (P = 0.040) were independent prognostic factors </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Prognosis of secondary <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> was different according to the type of the preceding disorders with the worst prognosis in <z:hpo ids='HP_0001909'>leukemia</z:hpo> following myeloprolfierative <z:hpo ids='HP_0002664'>neoplasm</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>Along with cytogenetic risk grouping, <z:mp ids='MP_0004027'>trisomy</z:mp> 8 had a poor prognostic impact in secondary <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> </plain></SENT>
</text></document>